BridgeBio Pharma Inc vs ProShares Ultra Bloomberg Natural Gas ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while ProShares Ultra Bloomberg Natural Gas ETF trades at $20.78. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | BOIL | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.17 | $87.24 |
52-Week Low | $47.29 | $18.74 |
Enterprise Value | $18.14B | — |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →